TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer
David Thomson, Clare Cruickshank, Helen Baines, Russell Banner, Matthew Beasley, Guy Betts, Helen Bulbeck, Frances Charlwood, Judith Christian, Matthew Clarke, Olly Donnelly, Bernadette Foran, Callum Gillies, Clare Griffin, Jarrod J. Homer, Johannes A. Langendijk, Lip Wai Lee, James C. Lester, Matthew Lowe, Andrew McPartlin, Elizabeth Miles, Christopher M. Nutting, Nachi Palaniappan, Robin Prestwich, James Price, Clare Roberts, Justin Roe, Ramkumar Shanmugasundaram, Rita Simões, Anna Thompson, Catharine West, Lorna Rachel Maven Wilson, Jane Wolstenholme, Emma Hall
Abstract
•There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.•Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.•There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.